Abstract
In therapeutics research, the nitro compounds are part of an important group of drugs with multiple pharmacological activities. However, in drug design, the inclusion of a nitro group in a molecule changes the physico-chemical and electronic properties and is associated with increased mutagenicity and carcinogenicity. In addition, several studies have related the relationship between the antimicrobial and/or anti-protozoal activity and the mutagenic effect to reduction of the nitro group. This work reviews the toxicity of nitro compounds and shows how the use of prodrugs can increase the biological activity and decrease the genotoxicity of nitro compounds, without any modification in nitro reduction behavior, but rather by physico-chemical improvement. Examples are given of metronidazole and nitrofurazone prodrugs.
Keywords: Prodrugs, nitro-compounds, metronidazol, nitrofurazone, genotoxicity, physico-chemical properties, nitroheterocyclic compounds, half-life, nitroimidazoles, Chagas disease
Current Pharmaceutical Design
Title: A Prodrug Approach to Improve the Physico-Chemical Properties and Decrease the Genotoxicity of Nitro Compounds
Volume: 17 Issue: 32
Author(s): Man Chin Chung, Priscila Longhin Bosquesi and Jean Leandro dos Santos
Affiliation:
Keywords: Prodrugs, nitro-compounds, metronidazol, nitrofurazone, genotoxicity, physico-chemical properties, nitroheterocyclic compounds, half-life, nitroimidazoles, Chagas disease
Abstract: In therapeutics research, the nitro compounds are part of an important group of drugs with multiple pharmacological activities. However, in drug design, the inclusion of a nitro group in a molecule changes the physico-chemical and electronic properties and is associated with increased mutagenicity and carcinogenicity. In addition, several studies have related the relationship between the antimicrobial and/or anti-protozoal activity and the mutagenic effect to reduction of the nitro group. This work reviews the toxicity of nitro compounds and shows how the use of prodrugs can increase the biological activity and decrease the genotoxicity of nitro compounds, without any modification in nitro reduction behavior, but rather by physico-chemical improvement. Examples are given of metronidazole and nitrofurazone prodrugs.
Export Options
About this article
Cite this article as:
Chin Chung Man, Longhin Bosquesi Priscila and Leandro dos Santos Jean, A Prodrug Approach to Improve the Physico-Chemical Properties and Decrease the Genotoxicity of Nitro Compounds, Current Pharmaceutical Design 2011; 17 (32) . https://dx.doi.org/10.2174/138161211798194512
DOI https://dx.doi.org/10.2174/138161211798194512 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections
Inflammation & Allergy - Drug Targets (Discontinued) Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Non-Surgical Treatment Options for Symptomatic Uterine Leiomyomas
Current Women`s Health Reviews Overview on Inhalable Nanocarriers for Respiratory Immunization
Current Pharmaceutical Design Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents MicroRNA in Cervical Carcinogenesis: Window of Therapeutic Potential
Current Women`s Health Reviews Assessment and Management of the Adnexal Mass in the Pediatric Population
Current Women`s Health Reviews Topical Targeting Therapies for Sexually Transmitted Diseases
Current Nanoscience Possibilities and Limits of Ovarian Reserve Testing in ART
Current Pharmaceutical Biotechnology Vaginitis Due to <i>Pichia fermentans</i> in a Patient Affected by Endometrial Cancer: A Novel Case Report
Current Women`s Health Reviews Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Comparison of Large Proteomic Datasets
Current Proteomics